Business Description
Yuhan Corp
ISIN : KR7000100008
Share Class Description:
YUHNF: Ordinary SharesTotal Employee Number:
2,123Compare
Compare
Traded in other countries / regions
000100.Korea IPO Date
2018-03-12Description
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.16 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | 1.1 | |||||
Interest Coverage | 6.75 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.52 | |||||
Beneish M-Score | -2.24 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.1 | |||||
3-Year EBITDA Growth Rate | 31.9 | |||||
3-Year EPS without NRI Growth Rate | 27.2 | |||||
3-Year Book Growth Rate | 3.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.06 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 1.48 | |||||
Cash Ratio | 0.52 | |||||
Days Inventory | 93.71 | |||||
Days Sales Outstanding | 106.1 | |||||
Days Payable | 49.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.5 | |||||
Shareholder Yield % | -0.2 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.88 | |||||
Operating Margin % | 4.81 | |||||
Net Margin % | 9.56 | |||||
EBITDA Margin % | 14.59 | |||||
ROE % | 9.67 | |||||
ROA % | 6.81 | |||||
ROIC % | 3.68 | |||||
3-Year ROIIC % | 8.1 | |||||
ROC (Joel Greenblatt) % | 20.2 | |||||
ROCE % | 10.47 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.76 | |||||
Forward PE Ratio | 46.95 | |||||
PE Ratio without NRI | 23.47 | |||||
Shiller PE Ratio | 46.68 | |||||
Price-to-Owner-Earnings | 48.43 | |||||
PS Ratio | 2.36 | |||||
PB Ratio | 2.3 | |||||
Price-to-Tangible-Book | 2.65 | |||||
Price-to-Operating-Cash-Flow | 37.78 | |||||
EV-to-EBIT | 20.81 | |||||
EV-to-EBITDA | 16.19 | |||||
EV-to-Revenue | 2.36 | |||||
EV-to-FCF | -2711.59 | |||||
Price-to-Projected-FCF | 3.79 | |||||
Price-to-Median-PS-Value | 0.93 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.86 | |||||
| Price-to-Net-Current-Asset-Value | 8.61 | |||||
Earnings Yield (Greenblatt) % | 4.81 | |||||
FCF Yield % | -0.04 | |||||
Forward Rate of Return (Yacktman) % | 7.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:YUHNF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Yuhan Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0 - 0 | ||
| Shares Outstanding (Mil) | 74.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Yuhan Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Yuhan Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| KRW 600.000000 Cash Dividend | 2026-02-26 | -- | ||
| 1.05:1 Stock Split | 2021-12-29 | -- | ||
| 1.05:1 Stock Split | 2020-12-29 | -- | ||
| 5:1 Stock Split | 2020-04-08 | -- | ||
| 1.05:1 Stock Split | 2019-12-27 | -- |
Show
Entries
Yuhan Corp Frequently Asked Questions
What is Yuhan Corp(YUHNF)'s stock price today?
The current price of YUHNF is $0.00. The 52 week high of YUHNF is $0.00 and 52 week low is $0.00.
When is next earnings date of Yuhan Corp(YUHNF)?
The next earnings date of Yuhan Corp(YUHNF) is .
Does Yuhan Corp(YUHNF) pay dividends? If so, how much?
Yuhan Corp(YUHNF) does not pay dividend.
Guru Commentaries on OTCPK:YUHNF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC | 2023-05-31 |
Articles on Yuhan Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers